Alector Inc (ALEC)

May 25, 2026

Number of shareholders of Alector, Inc. – DUS:0Z2 - TradingView

May 25, 2026

May 19, 2026

How The Alector (ALEC) Investment Story Is Shifting With Tau Readthroughs And BBB Shuttle Focus - Yahoo Finance

May 19, 2026

May 14, 2026

Polaris entities hold 4.85M ALEC shares (ALEC) — Amendment No.7 - Stock Titan

May 14, 2026

May 14, 2026

MSN - MSN

May 14, 2026

May 12, 2026

TradingKey - TradingKey

May 12, 2026

May 08, 2026

Alector Establishes $125 Million At-the-Market Offering - The Globe and Mail

May 08, 2026

May 08, 2026

Myles Minter Reiterates Hold on Alector as Late-Stage Trial Failures Trigger Pipeline Reset but Next-Gen Brain Carrier Platform Offers Long-Term Optionality - TipRanks

May 08, 2026

May 08, 2026

Alector (ALEC) Reports Q1 Revenue Shortfall Amidst Strategic Dev - GuruFocus

May 08, 2026

May 08, 2026

Alector, Inc. Announces $125 Million Common Stock Sales Agreement with TD Securities (USA) LLC - Minichart

May 08, 2026

May 08, 2026

Alector: Q1 Earnings Snapshot - theheraldreview.com

May 08, 2026

May 07, 2026

Alector posts first quarter 2026 financial results amid new business updates - Traders Union

May 07, 2026

May 07, 2026

Alector : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com

May 07, 2026

May 07, 2026

Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

May 07, 2026

May 07, 2026

Alector (NASDAQ: ALEC) establishes $125M stock ATM facility - Stock Titan

May 07, 2026

May 07, 2026

Alector (NASDAQ: ALEC) files $125M ATM offering with TD Cowen - Stock Titan

May 07, 2026

May 07, 2026

Alector (NASDAQ: ALEC) narrows Q1 2026 loss as it refocuses pipeline - Stock Titan

May 07, 2026

May 07, 2026

Alector Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times

May 07, 2026

May 07, 2026

Alector | 10-Q: Q1 2026 Earnings Report - Moomoo

May 07, 2026

May 07, 2026

Alector | 8-K: Alector Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo

May 07, 2026

May 07, 2026

Alector (NASDAQ: ALEC) Q1 2026 results, trial halt and ABC focus - Stock Titan

May 07, 2026

May 07, 2026

BRIEF-Alector Q1 Basic EPS USD -0.21 - TradingView

May 07, 2026

May 07, 2026

Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance

May 07, 2026

May 07, 2026

MSN Money - MSN

May 07, 2026

May 05, 2026

Transcript : Alector, Inc.Special Call - marketscreener.com

May 05, 2026

May 04, 2026

Alector Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView

May 04, 2026

May 04, 2026

Morgan Stanley Maintains Alector(ALEC.US) With Sell Rating, Raises Target Price to $2 - Moomoo

May 04, 2026

May 03, 2026

Five-Way Obesity Drug Shows Effectiveness in Mice; Alector Stops Alzheimer’s Trial - geneonline.com

May 03, 2026

May 03, 2026

Franklin Lexington Private Markets Fund's Alector Inc(ALEC) Holding History - GuruFocus

May 03, 2026

May 02, 2026

Morgan Stanley raises Alector stock price target on pipeline focus By Investing.com - Investing.com Australia

May 02, 2026

May 01, 2026

Morgan Stanley raises Alector stock price target on pipeline focus - Investing.com

May 01, 2026

May 01, 2026

Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Alector (ALEC) - The Globe and Mail

May 01, 2026

May 01, 2026

Failure of GSK-partnered Alzheimer’s drug a fresh setback for Alector - The Pharma Letter

May 01, 2026

Apr 30, 2026

Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC) and Alector (ALEC) - The Globe and Mail

Apr 30, 2026

Apr 30, 2026

Peninsula biotech Alector loses another Alzheimer's battle, shifts to earlier-stage programs - The Business Journals

Apr 30, 2026

Apr 30, 2026

Alector drops GSK-partnered Alzheimer’s drug (ALEC:NASDAQ) - Seeking Alpha

Apr 30, 2026

Apr 30, 2026

How The Alector (ALEC) Narrative Is Shifting Toward BBB Shuttle Programs And Execution Risk - Yahoo Finance

Apr 30, 2026

Apr 30, 2026

GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints - BioSpace

Apr 30, 2026

Apr 30, 2026

5AM Venture Management, LLC's Alector Inc(ALEC) Holding History - GuruFocus

Apr 30, 2026

Apr 30, 2026

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis - The Manila Times

Apr 30, 2026

Apr 29, 2026

Biopharmaceutical company Alector Inc. announced that it will discontinue its Phase II PROGRESS-AD clinical trial of its candidate drug Nivisnebart (development code AL101/GSK4527226) for the treatment of early-stage Alzheimer's disease. - Bitget

Apr 29, 2026

Apr 29, 2026

Alector to discontinue phase 2 trial of nivisnebart - marketscreener.com

Apr 29, 2026

Apr 29, 2026

Alector to Discontinue Phase 2 PROGRESS-AD Trial of - GlobeNewswire

Apr 29, 2026

Apr 29, 2026

Alzheimer’s drug study stops early after review finds low odds of success - Stock Titan

Apr 29, 2026

Apr 28, 2026

Cantor Fitzgerald upgrades Alector (ALEC) - MSN

Apr 28, 2026

Apr 28, 2026

Alector (NASDAQ: ALEC) sets 2026 virtual meeting on directors, auditor and say-on-pay - Stock Titan

Apr 28, 2026

Apr 27, 2026

BlackRock (ALEC) discloses 5.2% ownership of Alector common stock - Stock Titan

Apr 27, 2026

Apr 27, 2026

Alector gains as Cantor Fitzgerald upgrades on brain carrier platform - MSN

Apr 27, 2026